TRIAL DETAIL

Phase I Trial of Oral PX-866

Drug:
Trial Name:
Phase I Trial of Oral PX-866
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 06/01/2008
Age of Trial (yrs) 16.5
Treatment Phase:
Gleevec-resistant
Drug Category:
PI3K inhibitor
Strategy:
Block KIT Signal Path
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
PX-866-001
Sponsor:
Oncothyreon Inc.
Patient Contact:
See site contact info below
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
PX-866 is a small molecule inhibitor of PI-3K. This study is being conducted to determine the maximally tolerated dose of oral PX-866 when given once per day on days 1 to 5 and 8 to 12 over a 28-day cycle.
This trial is open to patients 18 and over.

Trial Links

Trial Results
 

Drug Information
PX-866 description page from Oncothyreon
 

Trial Sites

Name
Address
City
State
Zip
Country
1665 N. Ursula St.
Aurora
CO
80045
USA
1505 Holcombe Blvd.
Houston
TX
77030
USA